Paper28958502
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL and 17 others. Lancet Oncol, 2017. Cited by 998 papers, by iCite.
Cite this record
ConductScience Library. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Papers, record 28958502. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28958502
- Disease
- non-small cell lung carcinoma1,066 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
- PubMed
- Publication types
- Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Genes, erbB-1 | Major topic |
| Lung Neoplasms | Major topic |
| Quinazolines | Major topic |
| Quinazolinones | Major topic |
| Adult | |
| Aged | |
| Confidence Intervals | |
| Disease-Free Survival | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Female | |
| Gefitinib | |
| Humans | |
| Kaplan-Meier Estimate | |
| Male | |
| Maximum Tolerated Dose | |
| Middle Aged | |
| Mutation | |
| Prognosis | |
| Survival Analysis | |
| Treatment Outcome |
Source PubMed
Trials7
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01774721 | ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT04339829 | An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | Background | ClinicalTrials.gov | |
| NCT04358562 | Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib | Results | ClinicalTrials.gov | |
| NCT04619563 | A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients | Background | ClinicalTrials.gov | |
| NCT04640870 | The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib | Background | ClinicalTrials.gov | |
| NCT05271916 | First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | Background | ClinicalTrials.gov | |
| NCT06643416 | Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia | Background | ClinicalTrials.gov |
Comments and corrections5
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 28958503 | Treatment choice in EGFR-mutant non-small-cell lung cancer. | https://conductscience.org/library/papers/28958503 | PubMed |
| Comment in | 29304361 | Dacomitinib in NSCLC: a positive trial with little clinical impact. | https://conductscience.org/library/papers/29304361 | PubMed |
| Comment in | 29304363 | Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply. | https://conductscience.org/library/papers/29304363 | PubMed |
| Comment in | 29780702 | Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option. | https://conductscience.org/library/papers/29780702 | PubMed |
| Comment in | 29780706 | The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations. | https://conductscience.org/library/papers/29780706 | PubMed |
Cited by663
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 998 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42985096 | Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries. | Front Oncol | 2026 | https://conductscience.org/library/papers/42985096 | PubMed |
| 42894004 | Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42894004 | PubMed |
| 42871070 | Dacomitinib With or Without Dose Titration in Treatment-Naive Advanced EGFR-Mutated NSCLC - Primary Analysis of the ATORG-003 Phase 2 Trial. | JTO Clin Res Rep | 2026 | https://conductscience.org/library/papers/42871070 | PubMed |
| 42799075 | Traditional Chinese medicine reprograms the tumor microenvironment to overcome EGFR-TKI resistance: mechanisms and therapeutic perspectives. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42799075 | PubMed |
| 42734867 | Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials. | J Egypt Natl Canc Inst | 2026 | https://conductscience.org/library/papers/42734867 | PubMed |
| 42719457 | Integrating clinical outcomes with molecular simulations to guide the selection of non-classical EGFR-TKIs: A comprehensive analysis and development of treatment strategies. | Exp Ther Med | 2026 | https://conductscience.org/library/papers/42719457 | PubMed |
| 42611130 | "What really works for us?" exploring therapeutic strategies for non-small cell lung cancer: an umbrella review of systematic reviews and meta-analyses. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42611130 | PubMed |
| 42602055 | Treatment prioritization of chemotherapy-anchored regimens after EGFR-TKI failure in EGFR-mutant NSCLC: a systematic review, pairwise meta-analysis and Bayesian network meta-analysis with probabilistic multi-criteria decision analysis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42602055 | PubMed |
| 42588620 | Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588620 | PubMed |
| 42586967 | Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42586967 | PubMed |
| 42528591 | Research progress of small molecule targeted drugs for non-small cell lung cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42528591 | PubMed |
| 42444976 | First-line third-generation EGFR-TKIs for advanced EGFR-mutated non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42444976 | PubMed |
| 42435178 | Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges. | Adv Exp Med Biol | 2026 | https://conductscience.org/library/papers/42435178 | PubMed |
| 42420595 | Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance. | Acta Pharmacol Sin | 2026 | https://conductscience.org/library/papers/42420595 | PubMed |
| 42369726 | Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/42369726 | PubMed |
| 42352924 | Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42352924 | PubMed |
| 42317338 | Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance. | Front Immunol | 2026 | https://conductscience.org/library/papers/42317338 | PubMed |
| 42315733 | Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings. | Int J Clin Oncol | 2026 | https://conductscience.org/library/papers/42315733 | PubMed |
| 42305404 | Differential Treatment Effects by Smoking Status for NSCLC Therapies (2010-2023): A Meta-Analysis. | JTO Clin Res Rep | 2026 | https://conductscience.org/library/papers/42305404 | PubMed |
| 42291371 | Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42291371 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| DACOMITINIB | CHEMBL2105719 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2105719 | ChEMBL |
| CATEQUENTINIB | CHEMBL4303201 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL4303201 | ChEMBL |
| GEFITINIB | CHEMBL939 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL939 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28958502
GET https://conductscience.org/api/papers/v1/28958502/cited_by?page=2